Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects

Currently, in modern medicine, there has been a sharp increase in interest in the combined pathology of cardiovascular diseases (CVD) with other nosologies, such as diabetes mellitus, chronic kidney disease, and oncopathology. Over the past decades, there have been large positive shifts in survival in this cohort of patients. An integral specialty of cardio-oncology is rapidly developing, which is aimed at improving the results of treatment of oncological patients. Due to increased life expectancy and improved long-term prognosis in cancer patients, in particular, the adverse effects of anticancer therapy have attracted great attention from researchers. The causal relationship between cancer and CVD can be partly explained by a common profile of modifiable and non-modifiable risk factors. There is also strong evidence that a systemic inflammatory response is a common pathophysiological determinant of cancer and CVD. General risk factors for development and progression, as well as pathogenetic mechanisms, contribute to high mortality rates. Increasing knowledge of pathophysiological mechanisms will help elucidate the general molecular aspects of carcinogenesis and cardiovascular disease. This review presents general modifiable risk factors and current pathogenetic aspects of cardiovascular and oncological diseases.

[1]  J. Borrás,et al.  Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain , 2022, International journal of environmental research and public health.

[2]  K. Katanoda,et al.  Long-Term Projections of Cancer Incidence and Mortality in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2054: An Empirical Validation Approach , 2022, Cancers.

[3]  C. Relton,et al.  Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study , 2022, Breast Cancer Research.

[4]  Weihong Ren,et al.  Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche , 2022, Frontiers in Oncology.

[5]  Samuel L. Ricci,et al.  Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma , 2022, Cancers.

[6]  G. Boriani,et al.  2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). , 2022, European heart journal.

[7]  Cui Li,et al.  New insights into the prognosis of intraocular malignancy: Interventions for association mechanisms between cancer and diabetes , 2022, Frontiers in Oncology.

[8]  H. Wang,et al.  Risk Factors for the Comorbidity of Hypertension and Renal Cell Carcinoma in the Cardio-Oncologic Era and Treatment for Tumor-Induced Hypertension , 2022, Frontiers in Cardiovascular Medicine.

[9]  A. Hormati,et al.  Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide , 2022, Middle East journal of digestive diseases.

[10]  E. Duplus,et al.  Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target , 2021, International journal of molecular sciences.

[11]  Mingyue Zhu,et al.  IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma , 2021, Frontiers in Oncology.

[12]  D. Duplyakov,et al.  Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy , 2021, Russian Journal of Cardiology.

[13]  K. Sankaranarayanan,et al.  Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases—an updated systematic review , 2021, Journal of Genetic Engineering and Biotechnology.

[14]  A. Dopazo,et al.  Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. , 2021, Journal of the American College of Cardiology.

[15]  Karolina Krupa-Kotara,et al.  Impact of obesity on risk of cancer. , 2021, Central European journal of public health.

[16]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[17]  D. Hedeker,et al.  Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients , 2021, Breast cancer research : BCR.

[18]  B. Sipos,et al.  Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma , 2020, Journal of gastroenterology and hepatology.

[19]  Jeroen J. Bax,et al.  The cancer patient and cardiology , 2020, European journal of heart failure.

[20]  L. Kritharides,et al.  Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab , 2020, Journal of clinical medicine.

[21]  S. Larsson,et al.  Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants , 2020, PLoS medicine.

[22]  K. Guan,et al.  Role of Leptin in Cardiovascular Diseases , 2020, Frontiers in Endocrinology.

[23]  S. Shankar,et al.  The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives , 2020, Journal of cellular and molecular medicine.

[24]  Adenike O Eketunde Diabetes as a Risk Factor for Breast Cancer , 2020, Cureus.

[25]  B. Perillo,et al.  ROS in cancer therapy: the bright side of the moon , 2020, Experimental & Molecular Medicine.

[26]  Prakash Kulkarni,et al.  The Mitochondrion as an Emerging Therapeutic Target in Cancer. , 2020, Trends in molecular medicine.

[27]  Lei Deng,et al.  A population-based study of cardiovascular disease mortality risk in US cancer patients. , 2019, European heart journal.

[28]  P. Libby,et al.  Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[29]  F. Greten,et al.  Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.

[30]  S. Reddy,et al.  HDL and LDL: Potential New Players in Breast Cancer Development , 2019, Journal of clinical medicine.

[31]  D. Crossman,et al.  Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). , 2018, Journal of thoracic disease.

[32]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[33]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[34]  Xinqiang Han,et al.  Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy , 2017, npj Precision Oncology.

[35]  Y. Abed,et al.  Obesity and inflammation: the linking mechanism and the complications , 2016, Archives of medical science : AMS.

[36]  O. Tangvarasittichai,et al.  Tumor Necrosis Factor-Α, Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women , 2016, Indian Journal of Clinical Biochemistry.

[37]  Yi-Min Zhu,et al.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice. , 2014, World journal of diabetes.

[38]  R. Gottlieb,et al.  Mitochondrial therapeutics for cardioprotection. , 2011, Current pharmaceutical design.

[39]  A. Jemal,et al.  The global burden of cancer: priorities for prevention , 2009, Carcinogenesis.

[40]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[41]  U. Goldbourt,et al.  Is there an association between hypertension and cancer mortality? , 2002, The American journal of medicine.

[42]  Sadeer G. Al-Kindi,et al.  Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology. , 2016, Mayo Clinic proceedings.